Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B

Pleurodesis is the standard of care for non‐small cell lung cancer (NSCLC) patients with symptomatic malignant pleural effusion (MPE). However, there is no standard management for MPE uncontrolled by pleurodesis. Most patients with unsuccessful MPE control are unable to receive effective chemotherapy. Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of MPE. This multicenter, phase II study investigated the effects of bevacizumab plus chemotherapy in nonsquamous NSCLC patients with unsuccessful management of MPE.

• Publication year

  2020

• Venue

  Thoracic Cancer

• Publication date

  2020-05-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1759-7714.13472PMID 32421226PMCID 7327672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effectiveness of nanoparticle albumin-bound paclitaxel plus carboplatin in non-small lung cancer patients with malignant pleural effusion.

  2018cited by this paper
• Success rate of medical thoracoscopy and talc pleurodesis in malignant pleurisy: A single‐centre experience

  2018cited by this paper
• Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.

  2016cited by this paper
• A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.

  2016cited by this paper
• Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway*

  2016cited by this paper
• Important prognostic factors for survival in patients with malignant pleural effusion

  2015cited by this paper
• Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion

  2013cited by this paper
• Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion

  2013cited by this paper
• The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion

  2013cited by this paper
• Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer

  2012cited by this paper
• [Pleuritis carcinomatosa].

  2011cited by this paper
• Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis.

  2011cited by this paper
• Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.

  2010cited by this paper
• Monoclonal anti‐vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion

  2009cited by this paper
• Emerging paradigms in the management of malignant pleural effusions.

  2008cited by this paper
• Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach.

  2007cited by this paper
• Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.

  2007cited by this paper
• Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial.

  2006cited by this paper
• Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study.

  2006cited by this paper
• Vascular endothelial growth factor in pleural effusions of different origin

  2005cited by this paper
• Pleural effusion

  2005cited by this paper
• Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.

  2005cited by this paper
• Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

  2005cited by this paper
• Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions.

  2005cited by this paper
• Pleurodesis is inhibited by anti-vascular endothelial growth factor antibody.

  2005cited by this paper
• Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

  2004cited by this paper
• Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions.

  2004cited by this paper
• High Level of Vascular Endothelial Growth Factor in Hemorrhagic Pleural Effusion of Cancer

  2002cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

  2002cited by this paper
• Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

  2000cited by this paper
• Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions

  1999cited by this paper
• Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.

  1999cited by this paper
• A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer.

  1998cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine.

  1997cited by this paper
• Prognostic value of pleural effusion in patients with non-small cell lung cancer.

  1997cited by this paper
• Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861.

  1994cited by this paper

• Treatment of Malignant Pleural Effusions.

  2025cites this paper
• Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports

  2025cites this paper
• First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?

  2024cites this paper
• American Association of Bronchology and Interventional Pulmonology Essential Knowledge in Interventional Pulmonology Series: Selected Topics in Malignant Pleural Disease.

  2024cites this paper
• A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review

  2024cites this paper
• Single‐cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non‐small‐cell lung cancer

  2024influential citation
• Toll-like Receptor 2 Mediates VEGF Overexpression and Mesothelial Hyperpermeability in Tuberculous Pleural Effusion

  2023cites this paper
• Current status of and progress in the treatment of malignant pleural effusion of lung cancer

  2023cites this paper
• Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: A Bayesian network meta-analysis

  2023cites this paper
• Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion

  2023cites this paper
• 肺癌抗血管生成治疗：现状、进展与困惑

  2022cites this paper
• Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report

  2022cites this paper
• Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors

  2022cites this paper
• The role of angiogenesis in malignant pleural effusion: from basic research to clinical application.

  2022cites this paper
• Effect of Network-Based Positive Psychological Nursing Model Combined With Elemene Injection on Negative Emotions, Immune Function and Quality of Life in Lung Cancer Patients Undergoing Chemotherapy in the Era of Big Data

  2022cites this paper
• Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

  2022cites this paper
• Concurrent Blockade of Endothelial EGFR and VEGF Signaling on Malignant Associated Pleural Fluid Induced Angiogenesis: From Clinic to Bench

  2021cites this paper
• Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study

  2021cites this paper